Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 6, 2008, Pages 1669-1675

  Foley, Robert N ^a   Curtis, Bryan M ^b   Parfrey, Patrick S ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD; BLOOD TRANSFUSION; CANADA; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ERYTHROPOIESIS; EUROPE; FEMALE; HUMAN; KIDNEY DISEASE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TIME; TREATMENT OUTCOME;

ANEMIA; BLOOD TRANSFUSION; CANADA; CHRONIC DISEASE; EPOETIN ALFA; ERYTHROPOIESIS; EUROPE; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 58149345844     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02100508     Document Type: Article

References (19)

1. Higgins MR, Grace M, Ulan RA, Silverberg DS, Bettcher KB, Dossetor JB: Anemia in hemodialysis patients. Arch Intern Med 137: 172-176, 1977
2. Goodnough LT, Monk TG, Andriole GL: Erythropoietin therapy. N Engl J Med 336: 933-938, 1997
3. Follow Up to the January 3,2008 Communication About an Ongoing Safety Review Erythropoiesis-Stimulating Agents (ESAs) Epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp). Available at: http://www.fda.gov/cder/drug/infopage/RHE. Accessed March 2008.
4. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP: Transfusion medicine. First of two parts - blood transfusion. N Engl J Med 340: 438-447, 1999
5. Zhou YC, Cecka JM: Sensitization in renal transplantation. Clin Transplant 313-323, 1991
6. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16: 2180-2189, 2005
7. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469-475, 2002
8. World Health Organization: International Monitoring of Adverse Reactions to Drugs: Adverse Reaction Terminology, Uppsala, Sweden, World Health Organization Collaborating Centre for International Drug Monitoring, 1992
9. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
10. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
11. Foley RN, Parfrey PS, Morgan J, Barré, PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58: 1325-1335, 2000
12. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris. D, Burger HU, Scherhag A, CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
13. Canadian Erythropoietin Study Group: Associated between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300: 573-578, 1990
14. U.S. Food and Drug Administration: Summary Minutes of the Joint Meeting of the Cardiovasdular and Renal Drugs Advisory Committee with the Drug Safety and Risk Management Advisory Committee. Available at: http://w-ww.fda.gov/OHRMS/DOCKETS/AC/07/minutes/2007-4315ml-final.pdf. Accessed March 2008.
15. European Medicines Agency: Public Statement: Epoetins and the Risk of Tumour Growth Progression and Thromboembolic Events in Cancer Patients and Cardiovascular Risks in Patients with Chronic Kidney Disease. Available at: http://www. emea.europa.eu/pdfs/human/press/pus/ 49618807en.pdf. Accessed March 2008.
16. Tisher CC, Barnett BM, Finch CA, Scribner BH: Treatment of iron overload in patients with renal failure. Clin Sci 33: 539-548, 1967
17. Hakim RM, Stivelman JC, Schulman G, Fosburg M, Wolfe L, Imber MJ, Lazarus JM: Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis 10: 293-299, 1987
18. U.S. Renal Data System: USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007. Available at: http://www.usrds.org/2007/view/ 00a_precis.asp. Accessed March 2008.
19. Murphy SW, Foley RN, Barrett BJ, Kent GM, Morgan J, Barre P, Campbell P, Fine A, Goldstein MB, Handa SP, Jindal KK, Levin A, Mandin H, Muirhead N, Richardson RM, Parfrey PS:. Comparative mortality of hemodialysis and peritoneal dialysis in Canada. Kidney Int 57: 1720-1726, 2000